CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
I 型干扰素介导的肿瘤免疫及其在免疫治疗中的作用
英文原题：Type I interferon-mediated tumor immunity and its role in immunotherapy.
查看英文原题
Type I interferon-mediated tumor immunity and its role in immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫检查点阻断（ICB）疗法已在多种不同类型的癌症患者中取得了显著的临床应答；然而，大多数接受ICB单药治疗的患者未能获得长期应答，部分肿瘤出现免疫治疗耐药甚至超进展。I型干扰素（IFN）已被证明分别通过作用于肿瘤细胞和免疫细胞直接和间接抑制肿瘤生长。此外，越来越多的证据表明，内源性和外源性增强I型IFN对抗肿瘤免疫具有协同效应。因此，目前正在开展将I型IFN诱导剂与ICB联合的新治疗策略的临床试验。在此，我们综述了I型IFN的细胞来源及其在肿瘤微环境免疫调节中的作用。此外，我们重点介绍了基于I型IFN的免疫疗法以及I型IFN诱导剂与ICB之间的联合治疗。
展开英文摘要原文
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively.
Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity.
Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress.
Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment.
In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.
论文信息
- 作者
- Yu R、Zhu B、Chen D
- 第一作者单位
- Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.China
- 通讯作者单位
- Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. degaochen@tmmu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Cellular and molecular life sciences : CMLS2022 Mar 16
- 原文标识
- PubMed 35292881 · DOI 10.1007/s00018-022-04219-z
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →